Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where F de La Hoz is active.

Publication


Featured researches published by F de La Hoz.


Clinical Microbiology and Infection | 2014

Carbapenem resistance and mortality in patients with Acinetobacter baumannii infection: systematic review and meta-analysis

E.V. Lemos; F de La Hoz; Thomas R. Einarson; W.F. McGhan; Elkin Quevedo; C. Castañeda; Kosuke Kawai

Acinetobacter baumannii has emerged as a major cause of healthcare-associated infections. Controversy exists as to whether antimicrobial resistance increases the risk of mortality. We conducted a systematic review and meta-analysis to examine this association. We searched MEDLINE and EMBASE databases up to May 2013 to identify studies comparing mortality in patients with carbapenem-resistant A. baumannii (CRAB) vs. carbapenem-susceptible A. baumannii (CSAB). A random-effects model was used to pool Odds Ratios (OR). Heterogeneity was examined using I(2). We included 16 observational studies. There were 850 reported deaths (33%) among the 2546 patients. Patients with CRAB had a significantly higher risk of mortality than patients with CSAB in the pooled analysis of crude effect estimates (crude OR = 2.22; 95% CI = 1.66, 2.98), although substantial heterogeneity was evident (heterogeneity I(2) = 55%). The association remained significant in the pooled adjusted OR of 10 studies. Studies reported that patients with CRAB compared to patients with CSAB were more likely to have severe underlying illness and also to receive inappropriate empirical antimicrobial treatment, which increases the risk of mortality. Our study suggests that carbapenem resistance may increase the risk of mortality in patients with A. baumannii infection. However, cautious interpretation is required because of the residual confounding factors and inadequate sample size in most studies.


Value in Health | 2009

PIN18 IMPACTO EPIDEMIOLÓGICO Y ECONÓMICO DE LA INTRODUCCIÓN DE LA VACUNA DE INFLUENZA EN COLOMBIA

A Porras; Alejandro Rico; F de La Hoz; Nelson Alvis; J Orozco; L Alvis; C. Castañeda

PIN15 EVALUACIÓN ECONÓMICA DEL IMPACTO DE LA INTRODUCCIÓN DE LA VACUNA DE HEPATITIS A EN BOGOTÁ D.C de La Hoz F, Alvis N, Narváez J, Pérez B Universidad Nacional de Colombia, Bogotá D.C, Colombia, Universidad de Cartagena, Cartagena, Colombia OBJECTIVOS: Estimar la carga de enfermedad por hepatitis A en Bogotá y modelar el impacto epidemiológico y económico de la introducción de la vacuna de hepatitis A. METODOLOGÍAS: Estimación epidemiológica basada en una revisión sistemática de literatura de bases de datos nacionales e internacionales, y estudio de evaluación económica del impacto de la introducción de la vacuna. RESULTADOS: Se estimó que durante el 2007, en el escenario sin vacunación, en Bogotá se produjeron entre 59,333 y 73,192 casos de infección por hepatitis A en menores de 15 años. De éstos desarrollarían enfermedad ictérica entre 19,721 y 22,602, se generarían entre 3126 y 3531 hospitalizaciones, presentarían falla hepática entre 59 y 68, y se esperarían entre 36 y 41 muertes. El costo directo total de la atención de la carga de enfermedad por hepatitis A en Bogotá se estimó en US


Clinical Microbiology and Infection | 2014

Impact of carbapenem resistance on clinical and economic outcomes among patients with Acinetobacter baumannii infection in Colombia.

Elkin Lemos; F de La Hoz; Nelson Alvis; Thomas R. Einarson; Elkin Quevedo; C. Castañeda; Y. Leon; C. Amado; O. Cañon; Kosuke Kawai

2.97 millones (US


Actas Dermo-Sifiliográficas (English Edition) | 2012

Risk Factors for Basal Cell Carcinoma: A Study From the National Dermatology Center of Colombia

Guillermo Sánchez; John Nova; F de La Hoz

2.4–3.9 millones, US


Value in Health | 2009

PRS16 AN ECONOMIC EVALUATION OF A PHARMACOLOGICAL INTERVENTION USING VARENICLINE AS THERAPY FOR SMOKING CESSATION

J Narváez; Nelson Alvis; F de La Hoz; J Orozco; A Porras

de 2007). Si se introduce la vacunación con una dosis los costos de atención se reducirían en US


Value in Health | 2011

PIN22 COST-EFFECTIVENESS OF A CATCH-UP DOSE OF HEPATITIS B VACCINE IN COLOMBIAN ADOLESCENTS

Nelson Alvis; M. Romero; A. Paternina; F de La Hoz

2.5 millones y con dos dosis en US


Value in Health | 2010

PIN23 COST-EFFECTIVENESS OF PNEUMOCOCCAL VACCINE POLYVALENT (PPSV23) IN ADULTS OLDER THAN 60 YEARS OLD IN COLOMBIA

Nelson Alvis; F de La Hoz; C. Castañeda; A. Paternina

2.8 millones. La vacunación con cualquiera de los esquemas evitaría cerca de 34 muertes y 7 años de vida ajustados por discapacidad (AVAD). En los dos escenarios la vacunación resulta costo-ahorrativa. Con una dosis salvar un AVAD representa un ahorro de US


Value in Health | 2015

Burden of Disease and Economic Impact of Malaria In Colombia, 2012

P.E. Chaparro-Narváez; Diana Patricia Díaz; Carlos Castañeda-Orjuela; F de La Hoz

239 y evitar una muerte ahorra US


Value in Health | 2013

Vaccination coverage in colombia, opportunity and factors associated: Results from a national survey

F de La Hoz; B. Osorio; J Narváez

62,924; con dos dosis el ahorro sería de US


Value in Health | 2012

PIN20 Costs of Probable Bacterial Pneumonia in Children Under 5 Years Old in Colombia

Nelson Alvis; J.M. Orozco-Africano; Ángel Paternina-Caicedo; W. Coronell; D. Jervis-Jálabe; F de La Hoz

162 y US

Collaboration


Dive into the F de La Hoz's collaboration.

Top Co-Authors

Avatar

Nelson Alvis

University of Cartagena

View shared research outputs
Top Co-Authors

Avatar

J Narváez

National University of Colombia

View shared research outputs
Top Co-Authors

Avatar

A. Paternina

University of Cartagena

View shared research outputs
Top Co-Authors

Avatar

C. Castañeda

National University of Colombia

View shared research outputs
Top Co-Authors

Avatar

L Alvis

University of Cartagena

View shared research outputs
Top Co-Authors

Avatar

A Porras

National University of Colombia

View shared research outputs
Top Co-Authors

Avatar

Bibiana Pérez

National University of Colombia

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

W. Coronell

University of Cartagena

View shared research outputs
Researchain Logo
Decentralizing Knowledge